• Deciding whether Intuitive Surgical at around US$420 a share still makes sense for your portfolio, or if the price is hard to justify, starts with understanding what you are actually paying for.
• The stock is down 7.1% over the past week, 6.8% over the past month, and 25.3% year to date, with a 25.2% decline over the past year contrasting with gains of 36.4% over three years and 54.2% over five years.
• Recent coverage has focused on how Intuitive Surgical fits into long term themes in healthcare technology and on how investors are reassessing risk and reward after a stretch of weaker share price performance. Commentators have been weighing up whether the current valuation still reflects the company’s established position in robotic assisted surgery or if sentiment has moved ahead of fundamentals.
• Simply Wall St currently gives Intuitive Surgical a valuation score of 1 out of 6. The rest of this article will walk through common valuation approaches for the stock and then finish with a more complete way to think about its value that goes beyond any single metric.

Intuitive Surgical scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Intuitive Surgical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the cash the business may generate in the future and then discounting those cash flows back to today.

For Intuitive Surgical, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $2.3b. Analyst estimates and subsequent extrapolations point to free cash flow of around $6.1b in 2030, with intermediate projections for each year between 2026 and 2035 supplied by analysts and Simply Wall St estimates.

By discounting those projected cash flows back to today in dollars, the model arrives at an estimated intrinsic value of about $403.86 per share. Compared with the recent share price of around $420, this suggests the stock is approximately 4.0% above the DCF estimate, which is a relatively small difference rather than a wide gap.

Result: ABOUT RIGHT

Intuitive Surgical is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Intuitive Surgical Price vs Earnings

For profitable companies, the P/E ratio is a common yardstick because it links what you pay per share to the earnings that each share represents. It gives a quick read on how much the market is willing to pay for every dollar of current earnings.

What counts as a “normal” P/E depends on how investors view growth potential and risk. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher uncertainty usually lines up with a lower multiple.

Intuitive Surgical currently trades on a P/E of about 49.9x. That is above the Medical Equipment industry average P/E of around 23.4x and the peer average of about 24.6x, so on simple comparisons the stock carries a higher multiple than many sector peers.

Simply Wall St’s Fair Ratio for Intuitive Surgical is 32.2x. This is a proprietary P/E estimate that adjusts for factors such as earnings growth, industry, profit margin, market cap and company specific risks. Because it is tailored to the company, it can be more informative than a blunt comparison with industry or peer averages.

Comparing the current P/E of 49.9x with the Fair Ratio of 32.2x suggests the stock is trading above what that framework would imply.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Intuitive Surgical Narrative

Earlier sections walked through DCF and P/E. A more powerful way to think about Intuitive Surgical on Simply Wall St is to use Narratives, which let you attach a clear story about the company to your own revenue, earnings and margin assumptions, link those assumptions to a fair value, and then compare that fair value with the current price so you can judge whether the stock looks expensive or reasonable based on your view.

For Intuitive Surgical however we will make it really easy for you with previews of two leading Intuitive Surgical Narratives:

Fair value: about US$532.46 a share

Price vs this narrative fair value: around 21.0% below the fair value estimate

Revenue growth assumption: 12%

• Frames Intuitive Surgical as a long established leader in robotic assisted surgery with the da Vinci system at the core of a broader digital ecosystem for surgeons.
• Highlights a large installed base and high share of recurring revenue from instruments, services and software, which the author views as supporting a strong business model and moat.
• Even with a fair value estimate above the current price, the author is cautious about adding more shares at higher levels and focuses on expected long term returns versus personal return hurdles.

Fair value: about US$325.55 a share

Price vs this narrative fair value: around 29.0% above the fair value estimate

Revenue growth assumption: 12%

• Sees clear growth drivers in higher robotic surgery adoption, more procedures per system and new clinical indications, alongside expansion into additional geographies.
• Also flags risks such as high upfront system costs, regulatory and reimbursement changes, competition in surgical robotics and heavy reliance on the da Vinci platform.
• Concludes that the stock looks overvalued relative to this fair value estimate and that high expectations leave little room for disappointment if growth or margins soften.

If you want to see how other investors are weighing the same facts, and how these two views compare with the rest of the community, See what the community is saying about Intuitive Surgical.

Do you think there's more to the story for Intuitive Surgical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.